FingerMotion (NASDAQ:FNGR) reported $4.86 million in sales this quarter.
Goldman Sachs Maintains Neutral on Cerevel Therapeutics Hldg, Raises Price Target to $28
Goldman Sachs analyst Madhu Kumar maintains Cerevel Therapeutics Hldg (NASDAQ:CERE) with a Neutral and raises the price target from $24 to $28.